Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The TRIUMPH-4 Phase 3 trial in obesity with knee osteoarthritis (Bays et al., NEJM 2025) reported 28.7% mean weight loss at 68 weeks at the 12 mg dose, plus a 75.8% reduction in WOMAC knee pain scores
Wear sunscreen and sunglasses: Protect your skin by applying a broad-spectrum sunscreen daily, and wear UV-blocking sunglasses to shield your eyes from solar damage
Eryptosis is altered in peritoneal dialysis patients
Description Cagrilintide is an investigational, long-acting synthetic peptide that acts as a dual amylin and calcitonin receptor agonist (DACRA), primarily under development for the treatment of obesity and type 2 diabetes
US$ 20.63
US$ 22.28
US$ 23.47
US$ 25.69
US$ 25.79
